Page 101 - 2018_12-Haematologica-web

MYC inhibits miR-150 expression in CML
the transcription factor c-Myb. Cell. 2007;
131(1):146-159.
13. Gonda TJ, Metcalf D. Expression of myb,
myc and fos proto-oncogenes during the differentiation of a murine myeloid leukaemia. Nature. 1984;310(5974):249- 251.
14. Lidonnici MR, Corradini F, Waldron T, Bender TP, Calabretta B. Requirement of c- Myb for p210(BCR/ABL)-dependent trans- formation of hematopoietic progenitors and leukemogenesis. Blood. 2008; 111(9):4771-4779.
15. Vigorito E, Perks KL, Abreu-Goodger C, et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27(6):847-859.
16. Gerloff D, Grundler R, Wurm AA, et al. NF- kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2015;29(3):535-547.
17. Wolff L, Schmidt M, Koller R, et al. Three genes with different functions in transfor- mation are regulated by c-Myb in myeloid cells. Blood Cells Mol Dis. 2001;27(2):483- 488.
18. Sharma N, Magistroni V, Piazza R, et al. BCR/ABL1 and BCR are under the tran- scriptional control of the MYC oncogene. Mol Cancer. 2015;14:132.
19. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872- 884.
20. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34(2):374-378.
21. Lehár J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007;3:80.
22. Yuan H, Wang Z, Gao C, et al. BCR-ABL
gene expression is required for its muta- tions in a novel KCL-22 cell culture model for acquired resistance of chronic myeloge- nous leukemia. J Biol Chem. 2010; 285(7):5085-5096.
23. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a thera- peutic strategy to target c-Myc. Cell. 2011;146(6):904-917.
24. Kihara-Negishi F, Yamamoto H, Suzuki M, et al. In vivo complex formation of PU.1 with HDAC1 associated with PU.1-medi- ated transcriptional repression. Oncogene. 2001;20(42):6039-6047.
25. Bellon T, Perrotti D, Calabretta B. Granulocytic differentiation of normal hematopoietic precursor cells induced by transcription factor PU.1 correlates with negative regulation of the c-myb promoter. Blood. 1997;90(5):1828-1839.
26. Dahl R, Simon MC. The importance of PU.1 concentration in hematopoietic line- age commitment and maturation. Blood Cells Mol Dis. 2003;31(2):229-233.
27. Hornick NI, Doron B, Abdelhamed S, et al. AML suppresses hematopoiesis by releas- ing exosomes that contain microRNAs tar- geting c-MYB. Sci Signal. 2016;9(444):ra88.
28. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008; 40(1):43-50.
29. Jiang X, Huang H, Li Z, et al. Blockade of miR-150 maturation by MLL- fusion/MYC/LIN-28 is required for MLL- associated leukemia. Cancer Cell. 2012;22(4):524-535.
30. Adams CM, Hiebert SW, Eischen CM. Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies. Cancer Res. 2016;76(3):736-748.
31. Abraham SA, Hopcroft LE, Carrick E, et al. Dual targeting of p53 and c-MYC selective-
ly eliminates leukaemic stem cells. Nature.
2016;534(7607):341-346.
32. Albajar M, Gutierrez P, Richard C, et al.
PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett. 2008;270(2):328-336.
33. Yang H, Liang H, Yan JS, Tao R, Hao SG, Ma LY. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methy- lation in chronic myeloid leukemia. Int J Hematol. 2012;96(1):65-73.
34. Stopka T, Amanatullah DF, Papetti M, Skoultchi AI. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin struc- ture. EMBO J. 2005;24(21):3712-3723.
35. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005; 207(2):243-249.
36. Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood. 2009;114(23):4761-4770.
37. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257-2261.
38. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myelo- proliferative disorder. J Exp Med. 2008; 205(3):585-594.
39. Rokah OH, Granot G, Ovcharenko A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One. 2012;7(4):e35501.
40. Narayan N, Morenos L, Phipson B, et al. Functionally distinct roles for different miR-155 expression levels through con- trasting effects on gene expression, in acute myeloid leukaemia. Leukemia. 2017; 31(4):808-820.
haematologica | 2018; 103(12)
2025